title: Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management.
authors.forename: E
authors.initials: E
authors.lastname: Papadavid
authors.forename: S
authors.initials: S
authors.lastname: Gazi
authors.forename: M
authors.initials: M
authors.lastname: Dalamaga
authors.forename: N
authors.initials: N
authors.lastname: Stavrianeas
authors.forename: V
authors.initials: V
authors.lastname: Ntelis
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy; D005260:Female; D005528:Foot / Q000473:pathology; D006225:Hand / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008297:Male; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D012535:Scalp / Q000473:pathology; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab